Search

Displaying results 1511 - 1520 of 10000 in total
  1. Drug

    Adapalene

    go.drugbank.com/drugs/DB00210
    ApprovedInvestigational

    On December 8th, 2008, Galderma Labs gained FDA approval for Epiduo®, a 0.1% adapalene, 2.5% BPO combination gel.[L12873] … [A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution.

    Categories: Retinoids for Topical Use in Acne
  2. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    In clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [L940] … These resistance-associated amino acid substitutions included Q30D/deletion, Y93D/H/N or H58D +Y93H in genotype 1a replicons, F28S + M31I or P29S + K30G in genotype 2a replicons, and Y93H in genotype 3a

  3. Drug

    Elasomeran

    go.drugbank.com/drugs/DB15654
    ApprovedInvestigational

    [L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29). … [L28026] On December 23, 2020, Health Canada issued an expedited authorization for the Moderna COVID-19 Vaccine.

  4. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.

  5. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    FDA approved on December 21, 2012.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Deslanoside

    go.drugbank.com/drugs/DB01078
    Approved

    Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. … Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.

  8. Drug

    Propiverine

    go.drugbank.com/drugs/DB12278
    Approved

    Overactive bladder syndrome affects millions of elderly individuals in the United States and shows equal prevalence in men and women. … OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents [L2327], [L2328].

  9. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It gained approval by European Commission in March 2009. … Ligand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA.

  10. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    in which the patient develops an infection during a period of significant neutropenia. … chemotherapy-induced neutropenia, including FN.